Merck said on Wednesday that its experimental oral HIV treatment was not inferior to Gilead's top-selling HIV drug Biktarvy ...

A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...

African kingdom has accepted 15 men as part of a third-country deportation program. This program, which has been strongly ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said the treatment is a once-daily two-drug regimen of doravirine/islatravir that ...

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.

Funding for HIV care and prevention are key for continued progress, but recent cuts to federal funding for health agencies, ...

Indian River County recorded the highest rate of new cases on the Treasure Coast, with 14 per 100,000 people diagnosed with ...

Prof Nawangwe said Makerere University — ranked second in Africa and 63rd globally — continues to bolster its profile as a ...

Over 19,000 persons in the Bono Region are living with HIV and AIDS, according to the Bono, Bono East and Ahafo Regional ...